Gene Therapy Molecular Switch May Control Dosing
Researchers have developed a reversible RNA on-switch that could be embedded into gene therapies to control dosing.
Related Articles
Recipharm and Exela Pharma Sciences Form Exclusive CDMO Strategic Alliance
The strategic collaboration will provide Recipharm with access to Exela’s manufacturing facility located in Lenoir, NC.
Improving the Downstream Processing of Biological Products
Industry, academic institutions, suppliers, and regulatory agencies working together can yield state-of-the-art downstream processes.
Process Development Accelerates with Multidisciplinary Teamwork
KBI Biopharma says they’re selecting the best technologies to fill gaps in their processes with grassroots help from their scientific staff.
Intestinal Organoids Reveal Tuft Cells’ Role in Regeneration
Using miniature human intestines grown in the lab, tuft cells have been found to act as regenerative stem cells in the human intestine.
IMAC-Based Protein Purification
Researchers recommend verifying success of column-based purification to confirm the presence and availability of the tag on target protein.
Online Event
Detecting Alzheimer’s Disease (AD) before the symptoms of cognitive decline begin is essential for effective prevention. Highly sensitive, multiplex blood-based immunoassays can help with early-stage…
Aptadir Therapeutics Pioneers RNA Inhibitors That Target Hypermethylation in Rare Genetic Disorders
Aptadir engineers RNA therapies that inhibit DNMT-1 to prevent methylation in genes associated with myelodysplastic syndrome and other disorders.
Quell Therapeutics Taps eXmoor Pharma to Manufacture CAR-Tregs
Quell’s proprietary platform has been developed to generate engineered CAR-Treg cell therapies that can be directed to specific tissues.
Digital Twins of Biological Systems Inform Drug Development
Virtualization isn’t limited to industrial processes, such as biomanufacturing, it’s also a way to engage with biological systems—at multiple scales.
Digital Twins of Biological Systems Inform Drug Development
Virtualization isn’t limited to industrial processes, such as biomanufacturing, it’s also a way to engage with biological systems—at multiple scales.